“This is the first report of spindle cell sarcoma BRAF V600E/S607T double-mutated, responding to a combination of B-Raf and MEK inhibitors.” “This is the first report of spindle cell sarcoma BRAF ...

BRAF and MEK inhibitors are effective in treating resectable melanoma with BRAF V600 mutations, achieving significant pathological responses. The combination therapy significantly improves ...

The selective BRAF inhibitors vemurafenib (Zelboraf, Roche/Plexxikon) and dabrafenib (Tafinlar, GlaxoSmithKline) have significantly improved survival in patients with BRAF V600–mutant metastatic ...

LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...

“Inhibitors of GSK3β reduce the cell viability of BRAFi-resistant melanoma cell lines and thus may holds promise as a novel strategy to overcome BRAFi resistance and melanoma progression” “Inhibitors ...

In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...

BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration of response and progression-free ...

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today presented new ...

Nurix Therapeutics, Inc. presented promising preclinical data at the AACR 2025 Annual Meeting, showcasing their innovative targeted protein degradation medicines aimed at addressing various cancers, ...

WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...